BIO Submits Comments to FDA on Next Generation Sequencing
<p>
The Biotechnology Industry Organization (BIO) appreciates the opportunity to submit comments in association with FDA's public meeting entitled <em>Optimizing FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests.</em></p>